GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition.
性状
Solid
IC50 & Target[1][2]
IC50: ~6 nM (KMO)
体外研究(In Vitro)
GSK180 inhibits endogenous KMO activity in primary human hepatocytes (IC50=2.6 μM). GSK180 inhibits rat KMO slightly less potently than the human enzyme (IC50=7 μM).
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
GSK180 is proper for i.v. administration.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.